A study on the real world effect of the combination of bupropion hydrochloride sustained release tablets with behavior intervention on smoking cessation / 中国实用内科杂志

OBJECTIVE: To discuss the real world effect of bupropion hydrochloride sustained-release tablets and psychological intervention as well as WeChat publicity and follow-up on smoking cessation. METHODS: Totally 283 subjects were divided into two groups according to their own wishes: 84 people chose WeChant and psycholigical intervention, and were defined as control group; 199 people chose bupropion hydrochloride and WeChant and psycholigical intervention, and were defined as treatment group. The one-month smoking cessation rate and weight changes of the two groups in 3 months was compared, and the factors affecting the smoking cessation rate were analyzed. RESULTS: The success rate was 57.8% in treatment group, and the success rate of the control group was 10.7%. There was a statistically significant difference between the two groups. The average weight gain was 2.6 kg in the treatment group, and in the control group it was 3.5 kg, with no statistically significant difference. The presence of depression, intervention pattern, smoking-related disease, the number of cigarettes smoked per day, and the need to quit smoking for family members and the readiness to quit were statistically siginificant factors. The faliure rate of smoking cessation in depressed smokers was 7.772 times that of non-derpessed smokers, and it was4.492 times that of people with smoking related deseases. The failure rate of smoking cessation in people smoking more than20 cigarettes a day was 4.090 times that of pepople smoking less than 20. The failure rate in smokers without family requests of quiting smoking was 0.463 times that of those with requests; the failure rate in smokers without readiness was0.274 times that of those with proper readiness. The failure rate in control group was 14.292 times that of the treatment group. CONCLUSION: Bupropion hydrochloride sustained-release tablets + psychological intervention + WeChat platform promotion can significally increase the rate of sucessful smoking cessation. Factors affecting the success rate of smoking cessation are depression, intervention methods, smoking-related deseases, the number of cigarettes smoked, family requirements and smoking cessation preparations.

The distribution of Chinese medicine syndrome types in primary liver cancer and their differences of the survival time: a clinical study / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To explore the distribution of Chinese medicine (CM) syndrome types in primary liver cancer (PLC) and their differences of the survival time.</p><p><b>METHODS</b>From May 2007 to March 2009, recruited were 151 PLC inpatients at Department of Tumor, Guangdong Provincial Hospital of Traditional Chinese Medicine. Their survival time were statistically calculated. Patients' average survival time and median survival time were calculated using Kaplan-Meier method. The Log-rank test was used to analyze their differences of survival time among different CM syndrome types.</p><p><b>RESULTS</b>The proportion of CM syndrome types in PLC patients were ranked from high to low as follows: mutual accumulation of dampness and blood stasis syndrome [MADBSS, 43.0% (65/151)], Gan-stagnation Pi-deficiency syndrome [GSPDS, 34.4% (52/151)], qi stagnation blood stasis syndrome [QSBSS, 9.3% (14/151)], retention of damp-heat syndrome [RDHS, 8.6%(13/151)], and Gan-Shen yin deficiency syndrome [GSYDS, 4.6% (7/ 151)]. The median survival time of different CM syndrome types were ranked from longer to shorter as follows: GSPDS (14.77 months), QSBSS (6.13 months), RDHS (5.27 months), MADBSS (4.78 months), and GSYDS (0.80 months). The mean survival times were ranked from longer to shorter as follows: GSPDS (12.40 months), QSBSS (8.84 months), MADBSS (6.99 months), RDHS (7.08 months), and GSYDS (0.72 months). There was statistical difference in the difference of the survival time among different CM syndrome types (P < 0.05).</p><p><b>CONCLUSIONS</b>GSPDS and MADBSS were the most common CM syndrome types in PLC patients. There was difference in the survival time between GSPDS and MADBSS/between RDHS and GSYDS. There was difference in the survival time between MADBSS and GSYDS. Patients of GSPDS might get the best prognosis, while patients of GSYDS might get the poorest prognosis.</p>

An initial prevalence investigation of convulsive epilepsy in rural areas of Tibet Autonomous Region / 中华神经科杂志

Objective To find out the prevalence rate of epilepsy,its treatment gap and quality of life of epilepsy patients in rural areas of Tibet Autonomous Region (TAR).Methods Cluster sampling was adopted to conduct a door-to-door epidemiological survey among 14 822 rural population in Gangka town, Zhaxigang and Quzika village located in Medrogongka and Markham counties of TAR.The quality of life was measured by the 31-item quality of life in epilepsy inventory (QOLIE-31).Results Thirty-seven epilepsy patients were diagnosed as convulsive epileptic patients,and the prevalence was 0.25%.Thirty-five patients (94.59%) were diagnosed as active epilepsy,with a prevalence rate of 0.24%.Only one patient took standard Western Medicine within a week before the survey,and the treatment gap of the active epilepsy was 97.1%.The average QOLIE-31 total score was 42.15?17.63,and the lowest subcomponent score was 22.59?20.31 for seizure worry with the highest subcomponent score 85.83?18.59 for medication effects. Age,occupation,education,economic status,age at epilepsy onset and seizure frequency were significantly correlated with low QOLIE-31 scores (P

Reduced transcription of the RB2/p130 gene in human lung cancer.

Reduced expression of the retinoblastoma gene (RB)2/p130 protein, as well as mutation of exons 19, 20, 21, and 22 of the same gene, has been reported in primary lung cancer. However, it has been suggested by other investigators that mutational inactivation and loss of the RB2/p130 gene and protein, respectively, are rare events in lung cancer. In order to determine the contribution and mechanisms of RB2/p130 gene inactivation to lung cancer development and progression, we quantified RB2/p130 mRNA expression levels in a range of human lung cancer cell lines (n = 13) by real-time reverse transcription (RT)-polymerase chain reaction (PCR) analysis. In comparison to normal lung tissue, reduced transcription of the RB2/p130 gene was found in all small cell lung cancer cell lines examined, along with six out of the eight nonsmall cell lung cancers tested, most of which had inactivation of RB/p16 pathway. On the basis of Western blot analysis, the expression of RB2/p130 protein was consistent with RNA expression levels in all lung cancer cell lines examined. In addition, the mutational status of the RB2/p130 gene (specifically, exons 19, 20, 21, and 22) was determined in 30 primary lung cancers (from patients with distant metastasis) and 30 lung cancer cell lines by PCR-single strand conformation polymorphism (SSCP) analysis and direct DNA sequencing. There was no evidence of somatic mutations within the RB2/p130 gene in the 60 lung cancer samples (both cell lines and tumors) assessed, including the 11 lung cancer cell lines that displayed reduced expression of the gene. Furthermore, hypermethylation of the RB2/p130 promoter was not found in any of the above-mentioned 11 cell lines, as determined by a DNA methylation assay, combined bisulfite restriction analysis (COBRA). The results of the present study suggest that the reduced RB2/p130 expression seen in lung cancer may be in part transcriptionally mediated, albeit not likely via a mechanism involving hypermethylation of the RB2/p130 promoter. The observed reduction in RB2/p130 gene expression may be due to histone deacetylation, altered mRNA stability, and/or other forms of transcriptional regulation.

Generation of high affinity humanized single-chain antibody against PreS1 of hepatitis B virus from immune phage displayed antibody library / 中华肝脏病杂志

<p><b>OBJECTIVE</b>Screening and characterizing high affinity completely humanized single-chain antibody (ScFv) against PreS1 of hepatitis B virus.</p><p><b>METHODS</b>A combinatorial library of phage-displayed human ScFv, genes of which were derived from peripheral blood lymphocytes immunized by PreS1 of Hepatitis B Virus in vitro, was constructed. The library contained 7 10(8) clones.</p><p><b>RESULTS</b>After 3 rounds panning, a high affinity (K=10(7) to 10(8) mol/L) ScFv specific to PreS1 was obtained. The V(H) belonged to human V(H4) family, and V(1) to V(4) by sequence analysis.</p><p><b>CONCLUSION</b>This study suggests that the method of antigen stimulation in vitro is an expeditious way for the source of human immune antibody. And the ScFv may provide a more satisfactory therapy.</p>

Clinical observation on the efficacy enhancing and toxicity attenuating effect of nuzhen yangyin granule to the anti-parkinsonism therapy mainly with Medopa / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To observe and assess the efficacy enhancing and toxicity attenuating effect of Nuzhen Yangyin Granule (NYG) to the anti-parkinsonism (paralysis agitans) therapy with Medopa and Artane.</p><p><b>METHODS</b>Adopting the randomized double-blinded method, the effect of adding NYG to 30 patients with Parkinsonism in the treated group, who already received anti-Parkinsonism treatment but showing decreased response to Medopa and Artane and with obvious adverse reaction, was observed and controlled by 30 patients treated by adding placebo.</p><p><b>RESULTS</b>The total effective rate in the treated group and the control group was 86.7% and 56.7% respectively, the total syndrome improving rate was 90% and 56.7% respectively and the toxicity attenuating rate 90% and 43.3% respectively, comparison between the two groups showed significant difference (P < 0.05 or P < 0.01). NYG also showed markedly effective in reducing the adverse reactions of Medopa and Artane on digestive, neuro-psychiatric and cardiovascular system.</p><p><b>CONCLUSION</b>NYG has obvious efficacy enhancing and toxicity attenuating effects caused by the anti-Parkinsonism treatment with Medopa and Artane.</p>